RLYB
HEALTHCARERallybio Corp
Live · NASDAQ · May 9, Close
What's Moving RLYB Today?
No stock-specific AI insight has been generated for RLYB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$14.56
Fundamentals
Trading
RLYB News
20 articles- Rallybio to acquire Candid TherapeuticsPharmaceutical-technology·Mar 3, 2026
- Rallybio Corporation and Candid Therapeutics Announce Merger AgreementYahoo Finance·Mar 2, 2026
- Candid, in a reverse merger with RallyBio, to go publicBiopharmadive·Mar 2, 2026
- Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal ComplementYahoo Finance·Feb 17, 2026
- Stock Splits Matter: What’s Coming Up This Month?247 Wall St·Feb 4, 2026
- Rallybio Announces Reverse Stock Split of Common StockYahoo Finance·Feb 3, 2026
- Rallybio Reports Third Quarter 2025 Financial Results and Provides Business UpdatesYahoo Finance·Nov 6, 2025
- Does Short Squeeze Attention and AI Advances Alter the Bull Case for Recursion Pharmaceuticals (RXRX)?Yahoo Finance·Sep 27, 2025
- Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic StudyYahoo Finance·Sep 25, 2025
- Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 AdvancesYahoo Finance·Sep 21, 2025
- Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 ProgramYahoo Finance·Sep 3, 2025
- Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical CandidYahoo Finance·Aug 17, 2025
- Rallybio First Half 2025 Earnings: US$0.43 loss per share (vs US$0.83 loss in 1H 2024)Yahoo Finance·Aug 9, 2025
- Rallybio Reports Second Quarter 2025 Financial Results and Provides Business UpdatesYahoo Finance·Aug 7, 2025
- Recursion Reports Second Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Aug 5, 2025
- Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder HypophosphatasiaYahoo Finance·Jul 21, 2025
- Recursion Pharmaceuticals Rises 6% in a Month: How to Play the StockYahoo Finance·Jul 17, 2025
- Recursion Pharmaceuticals (RXRX) Rallies 8.7% on HypophosphatasiaYahoo Finance·Jul 9, 2025
- RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia ProgramYahoo Finance·Jul 9, 2025
- Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25MYahoo Finance·Jul 9, 2025
All 20 articles loaded
Price Data
52-Week Range
$14.56
Fundamentals
Trading
About Rallybio Corp
Rallybio Corp is a clinical-stage biotechnology company dedicated to developing innovative therapies for rare diseases with a particular emphasis on unmet needs in immunology and hematology. The company features a promising pipeline of biologic drug candidates progressing through various clinical stages, supported by a highly experienced management team with extensive industry expertise. Strategic partnerships enhance Rallybio's ability to deliver transformative treatments, reinforcing its commitment to underserved therapeutic areas. With a clear focus on improving patient outcomes, Rallybio is strategically positioned to make a meaningful impact in the healthcare landscape while advancing toward commercial viability.